retatrutide nejm 2023 obesity trial ly3437943 just posted the biggest weight-loss numbers ever recorded for a drug — 28.3% (≈70 lb) average in Phase 3, with 45% of people hitting 30%+ loss, territory once reserved for bariatric Retatrutide Triple Hormone Receptor Agonist:

A placebo is a harmless, inactive substance that looks like the drug being tested but has no effect

Azab, W

The apparent stimulation of EGR-1 expression by BPC-157 may suggest a hypothetical mechanism by which it may possibly improve wound healing

Glossary CKD Chronic kidney disease CVD Cardiovascular disease FDA Food and Drug Administration GLP-1 Glucagon-like peptide-1 GLP-1s Glucagon-like peptide-1 receptor agonists HF Heart failure MASH Metabolic dysfunction-associated steatohepatitis OA Osteoarthritis OSA Obstructive sleep apnea PAD Peripheral arterial disease SC Subcutaneous T2DM Type 2 diabetes mellitus U.S